Biodexa Pharmaceutical (NASDAQ: BDRX) shares will rise 8,000% at the open. BDRX stock will, unfortunately, only in a purely nominal sense. The real price could stay static, could rise or- horrors - actually fall here. The aim and intention here is simply to retain the NASDAQ quotation, nothing as interesting or important as actually trying to make shareholders some money.
The business line for Biodexa: “Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme;” Well, OK, so why is a Belgian company on NASDAQ? Because that's the best place, globally, to gain the risk capital to do this sort of pharma work. This hasn't been of a grand benefit to investors on NASDAQ of course - the BDRX stock price is down 99.5% over the past 12 months. You know, pretty much an entire wipeout. But that, in itself, creates a problem.

Biodexa Pharmaceutical stock price from NASDAQ. Note this is after consolidation.
That problem is that penny stocks are very much frowned upon in New York. There's an association with the disreputable, even the fraudsters in investors' minds. The result of this is that to stay on NASDAQ or the NYSE you must meet the $1 minimum bid price. As NASDAQ is where you can raise new capital it's worth trying to keep that quotation - that's what the company is on the exchange for after all, to raise capital. So, when the share price is down at 7 cents, which Biodexa was at yesterday, something must be done.
That something is the following: “Biodexa Pharmaceuticals plc. (BDRX) will effect a one-for-eighty (1-80) reverse split of its American Depositary Shares and a ratio change from one (1) ADS representing five (5) Ordinary Shares (1:5) to one (1) ADS representing four hundred (400) Ordinary Shares (1:400). The reverse stock split will become effective on Wedneday, July 5, 2023. In conjunction with the reverse split, the CUSIP number will change to 59564R708.” The share price alone will rise 8,000% therefore on a purely mechanical basis. Given the ADR ration change as well the NASDAQ quote will be a little different - we leave that price change as an exercise for the reader.
The important thing for us to remember as investors is that this price move is a purely nominal one. So, don't go trading Biodexa as some wondrous new meme stock - it isn't.